Objective: Given the significant economic, healthcare, and personal burden of acute and chronic wounds, we investigated the dose dependent wound healing mechanisms of two Avena Sativa derived compounds: Avenanthramide (AVN) and β-Glucan.
Approach: We utilized a splinted excisional wound model that mimics human-like wound healing and performed subcutaneous AVN and β-Glucan injections in 15-week-old C57BL/6 mice. Histologic and immunohistochemical analysis was performed on the explanted scar tissue to assess changes in collagen architecture and cellular responses.
Results: AVN and β-Glucan treatment provided therapeutic benefits at a 1% dose by weight in a PBS vehicle, including accelerated healing time, beneficial cellular recruitment, and improved tissue architecture of healed scars. 1% AVN treatment promoted an extracellular matrix (ECM) architecture similar to unwounded skin, with shorter, more randomly aligned collagen fibers, and reduced inflammatory cell presence in the healed tissue. 1% β-Glucan treatment promoted a tissue architecture characterized by long, thick bundles of collagen with increased blood vessel density.
Innovation: AVN and β-Glucan have previously shown promise in promoting wound healing, although the therapeutic efficacies and mechanisms of these bioactive compounds remain incompletely understood. Furthermore, the healed ECM architecture of these wounds has not been characterized.
Conclusions: AVN and β-Glucan accelerated wound closure compared to controls through distinct mechanisms. AVN treated scars displayed a more regenerative tissue architecture with reduced inflammatory cell recruitment, while β-Glucan demonstrated increased angiogenesis with more highly aligned tissue architecture more indicative of fibrosis. A deeper understanding of the mechanisms driving healing in these two naturally derived therapeutics will be important for translation to human use. .